Cipla said that the manufacturing of the drug Lanreotide is being temporarily stopped to support the USFDA remediation at the facility which produces the said drug.
Lanreotide is one of Cipla's top three products in the US market. The US market itself contributed to 27% of Cipla's topline in financial year 2025, registering record sales of $934 million during the previous year. During the September quarter this year, US sales for Cipla stood at $233 million from $230 million respectively.
The US Food and Drug Administration (USFDA) inspection at Pharmathen's Rodopi facility in
Pharmathen is a contract manufacturer (CDMO) and is the exclusive supplier of the Lanreotide to Cipla. The exchange filing went on to add that the re-supply of Lanreotide is expected to resume in the first half of financial year 2027.
"The company will closely monitor supply levels and is fully committed to restoring stable, reliable supply of Lanreotide expeditiously," Cipla stated in its filing.
Cipla has a 22% market share in Lanreotide in the US market.
Shares of Cipla ended 1% lower on Wednesday at ₹1,433.5. The stock has already declined 4.5% during the first 10 sessions of 2026.
